Skip to content
StockMarketAgent
Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

TELO stock hub

Telomir Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

TELOis not in this month’s coverageGet our monthly research letter — no spam
Fair value midpoint
n/a
Fair value pending
Upside to midpoint
n/a
Based on latest report
Confidence
n/a
Data quality and model convergence
Market cap
44.7M
NASDAQ
Market data

Live price

Current market quote for this ticker.

Current price
TELO
In the news

Latest news · TELO

Recent company headlines from major financial publishers.

Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window
EPS estimate
Revenue estimate
Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a
P25 12.3P50 18.4P75 33.1
Trailing P/En/a
P25 14.9P50 23.2P75 38.5
ROE-317.6
P25 -105.6P50 -46.5P75 -3.1
ROIC-184.9
P25 -63.1P50 -27.3P75 0.5
Benchmarks - 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
Indicator catalog

All TELO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields
152
Groups with data
11
Currency
USD
Showing 152 of 152 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

22
MetricValue
Cik
0001971532
Company name
Telomir Pharmaceuticals, Inc.
Country
United States
Country code
US
Cusip
87975F104
Employees
9
Enterprise value
$37.9M
Exchange
NASDAQ
Financial currency
USD
First seen
2026-05-09
Industry
Biotechnology
IPO Date
2024-02-09
Isin
US87975F1049
Last refreshed
2026-05-10
Market cap
$44.7M
Market cap category
Nano-Cap
Price
$1.3
Price currency
USD
Sector
Healthcare
Sic
2834
Symbol
TELO
Website
https://telomirpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

2
MetricValue
Earnings Yield
-23.3%
P/B ratio
7.56x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

8
MetricValue
Net Income
$-10.4M
Net Income Growth Quarters
2%
Net Income Growth Years
1%
Profit Per Employee
$-1.2M
ROA
-152
ROCE
-178.2
ROE
-317.6
ROIC
-184.9

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

4
MetricValue
Cagr1y
-47.81%
EPS Growth Quarters
2
EPS Growth Years
1
Revenue Growth Years
0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

17
MetricValue
Assets
$7.3M
Cash
$7.3M
Current Assets
$7.3M
Current Liabilities
$1.4M
Debt
$473,752
Debt Equity
$0.08
Equity
$5.9M
Liabilities
$1.4M
Long Term Assets
$0
Long Term Liabilities
$0
Net Cash
$6.8M
Net Cash By Market Cap
$15.24
Net Cash Growth
480.96%
Net Debt Equity
$-1.15
Tangible Book Value
$5.9M
Tangible Book Value Per Share
$0.17
WACC
3.09

Liquidity

Current-asset coverage and working-capital efficiency metrics.

4
MetricValue
Current ratio
5.14
Net Working Capital
$-899,548
Quick ratio
5.1
Working Capital
$5.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

1
MetricValue
Buyback Yield
-7.16%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

34
MetricValue
1Y total return
-47.79%
200-day SMA
1.4
50-day SMA
1.33
50-day SMA vs 200-day SMA
50under200
All Time High
20.72
All Time High Change
-93.73%
All Time High Date
2024-02-14
All Time Low
1.05
All Time Low Change
23.81%
All Time Low Date
2026-02-12
ATR
0.09
Beta
-0.21
Beta1y
0.85
Beta2y
1.42
Ch YTD
-2.26
High
1.35
High52
3.1
High52 Date
2025-07-18
High52ch
-58.06%
Low
1.3
Low52
1.05
Low52 Date
2026-02-12
Low52ch
23.81%
Ma50ch
-2.18%
Price vs 200-day SMA
-7.28%
RSI
44.2
RSI Monthly
30.65
RSI Weekly
45.36
Sharpe ratio
-0.11x
Sortino ratio
-0.16
Tr YTD
-2.26
Tr1m
-1.52%
Tr1w
-7.14%
Tr3m
13.04%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

2
MetricValue
Earnings EPS Estimate
$-0.07
Operating Income
$-10.5M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

11
MetricValue
Float
19,027,632%
Float Percent
55.34%
Net Borrowing
155,518
Shares Insiders
14.83%
Shares Institutions
6.68%
Shares Out
34,380,971
Shares Qo Q
3.38%
Shares Yo Y
7.16%
Short Float
5.47%
Short Ratio
12.95
Short Shares
3.03

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

47
MetricValue
Average Volume
242,427.6x
Bv Per Share
0.17
Ch1m
-1.52
Ch1w
-7.14
Ch1y
-47.79
Ch3m
13.04
Ch6m
-0.76
Change
-1.52%
Change From Open
-2.26
Close
1.32
Days Gap
0.76
Dollar Volume
99,546.2
Earnings Date
2026-05-12
Earnings Time
amc
EBIT
$-10.5M
EPS
$-0.33
F Score
2
Financing CF
9,708,727
Fiscal Year End
December
Founded
2,021
Ipr
-81.43
Iprfo
-81.43
Is Primary Listing
1
Is Spac
No
Last Earnings Date
2026-03-17
Last Report Date
2025-12-31
Last Split Type
Never
Last10k Filing Date
2026-03-17
Ma150
1.36
Ma150ch
-4.34%
Ma20
1.37
Ma20ch
-5.39%
Net CF
6,020,539
Next Earnings Date
2026-05-22
Open
1.33
Optionable
No
Position In Range
0
Post Close
1.3
Postmarket Change Percent
6.15
Postmarket Price
$1.38
Price Date
2026-05-08
Ptbv Ratio
7.56
Relative Volume
0.32x
Share Based Comp
6,130,329
Tr6m
-0.76%
Us State
Florida
Volume
76,574
Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate
n/a
Named kill scenarios are reviewed before any bullish rating can stand.
Moat score
n/a
Business quality stays separate from stock attractiveness.
Forward P/E
n/a
Valuation uses the full report model stack, not a single multiple.
Next action
Research pending
Final action steps are kept in the recommendation tab.
Income

Does TELO pay a dividend?

Capital-return profile for this ticker.

Performance

TELO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

1Y total return
-47.8%
S&P 500 1Y: n/a
3Y total return
n/a
S&P 500 3Y: n/a
5Y total return
n/a
S&P 500 5Y: n/a
10Y total return
n/a
S&P 500 10Y: n/a
Ownership

Who owns TELO?

Insider, institutional, and short-interest positioning.

Institutional ownership
+6.7%
Float: +55.3% of shares outstanding
Insider ownership
+14.8%
Stake held by company insiders. Higher generally signals alignment.
Short interest
+5.5%
12.9 days to cover
Y/Y dilution
+7.2%
Negative means the company is buying back shares.
Technical

TELO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)
44.2
Neutral momentum band
Price vs 200-day MA
-7.3%
50/200-day relationship not available
Beta (5Y)
-0.21
Less volatile than the market
Sharpe ratio
-0.11
Risk-adjusted return — higher is better; >1.0 is solid.
Questions

About TELO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current TELO stock rating?

Telomir Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full TELO analysis?

The full report lives at /stocks/TELO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for TELO?

The latest report frames TELO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the TELO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.